M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Dermatology company Sol-Gel Technologies Ltd (NASDAQ:SLGL) revealed on Thursday that it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX:MYX) for the sale and exclusive license of the US rights to EPSOLAY and TWYNEO.
The deal follows the...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search